Histopathological and immunohistochemical analysis of clinical melanoma evaluation;Analise imunohistopatologica, clinica e evolutiva dos melanomas

Anais Brasileiros de Dermatologia

Volumn 72, Issue 2, 1997, Pages 117-126

  Ferreira, Carlos Marcelo Martins ^a,c   Maceira, Juan Manuel Piñeiro ^a   De Oliveira Coelho, Janice Mery Chicarino ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c Hospital Evandro Chagas ^*  (Brazil)

Author keywords

immunohistochemistry; melanoma; neoplasm metastasis

Indexed keywords

PROTEIN S 100 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PROGNOSIS;

EID: 0031008728     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Schmoeckel C, Bockelbrink A, Bockelbrink H, Koutsis J, Braun-Falco O. Low- and High-risk Malignant Melanoma-I. Evaluation of Clinical and Histological Prognosticators in 585 Cases. Eur J Cancer et Clin Oncol 1983;19(2):227-35.
2. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A Multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow staging methods. Ann Surg 1978;188(6):732-42.
3. Clark WHJ, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-26.
4. Breslow A. Thickness, cross-sectional areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma. Ann Surg 1970;172(5):902-8.
5. Day CL, Mihm MC, Lew RA et al. Prognostic factors from patients with clinical stage I melanoma of intermediated thickness (1,51-3,99mm). A conceptual model for tumor growth and metastasis. Ann Surg 1982;195(1):35-43.
6. Balch CM, Soong SJ, Milton GW et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196(6):677-84.
7. Shaw HM, Balch CM, Soong S-T, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 1985;17:271-4.
8. Heenan PJ, Jarvis LR, de Klerk NH, Armstrong BK. Nuclear indices and survival in cutaneous melanoma. Am J Dermatopathol 1989;11(4):308-12.
9. Harrist TJ, Rigel DS, Day CL et al. "Microscopic satellites" are more highly associated with regional lymph nodes mestatases than is primary melanoma thickness. CANCER 1984;53:2183-7.
10. Day CL, Harrist TJ, Gorstein F et al. Malignant melanoma. Prognostic significance of "Microscopic Satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981;194(1):108-12.
11. Elder ED. Distinguishing cancer and noncancer. J Invest Dermatol 1985;85(1):1-3.
12. Brodland DG, Zitelli JA. Mechanisms of metastasis. J Am Acad Dermatol 1992;27(1):1-8.
13. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(7):495-7.
14. Murphy GF. Immunodiagnosis in Dermatopathology. Arch Dermatol 1985;121(6):731-3.
15. Vennegor C, Calafat J, Hageman P et al. Biochemical characterization and cellular localization of a formalin-resistant melanoma associated antigen reacting with monoclonal antibody NKI/C3. Int J Cancer 1985;35:287-95.
16. Hersey P. Review of melanoma antigenes recognized by monoclonal antibodies (MoAbs). Their functional significance and applications in diagnosis and treatment of melanoma. Pathology 1985;17:346-54.
17. Gaynor R, Irie R, Morton D, Herschman HR. S-100 protein is present in cultured human malignant melanomas. Nature 1980;286(24):400-1.
18. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus, and Its diagnostic application. CANCER 1982;50:912-8.
19. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodiesspecific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
20. Rutowisch MS. Marcadores imunohistoquímicos em melanomas primitivos e metastáticos. Tese de Doutorado. Rio de Janeiro: UFRJ, 1991;113pg.
21. Rode J, Dhillon AP. Neurone specific enolase and S-100 protein as possible prognostic indicators in melanoma. Histopathology 1984;8:1041-52.
22. Hagen EC, Vennegor C, Schlingemann RO, Van Der Velde EA, Ruiter DJ. Correlation of histopathological characteristics with staining patterns in human melanoma assessed by (monoclonal) antibodies reactive on paraffin sections. Histopathology 1986;10:689-700
23. Colombari R, Bonetti F, Zamboni G et al. Distribution of melanoma specificantibody (HMB-45) in benign and malignant melanocytic tumors. An immunohistochemical study on paraffin sections. Virchows Archiv A Pathol Anat 1988;413:17-24.
24. Lever WF, Schaumberg-Lever G. Histopathology of The Skin. 7th ed. Philadelphia: Lippincott, 1991.
25. Kontron Electronic Group. Image analysis systems. Mini-Mop Manual Rel. 1.0, April 1985.
26. Ordóñez NG, Xialong J, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988;90(4):385-90.
27. Vennegor C, Hageman P, Van Nouhuijs H et al. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol 1988;130:179-92.
28. Paul E, Cochran AJ, Wen DR. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi. J Cutan Pathol 15:161-5.
29. Palazzo JP, Duray PH. Congenital agminated Spitz nevi: immunoreactivity with a melanoma-associated monoclonal antibody. J Cutan Pathol 1988;15:166-70.
30. Rigel DS, Friedman RJ. Malignant melanoma. In: Julius Stone, Dermatologic immunology and allergy. Mosby Company, 1985; 795-914.
31. Sober AJ, Rhodes AR, Mihm MC, Fitzpatrick TB. Neoplasms: malignant melanoma. Dermatology in general medicine 3rd ed. New York: McGraw-Hill, 1987;947-66.
32. Sanderson KV, MacKie RM. Tumors of the skin. In: Rook A, Wilkinson DS, Ebling FJG. Textbook of Dermatology, 3rd ed London: Blackwell Scientific, 1979;2200-13.
33. Nasser N. Epidemiologia do melanoma maligno em Blumenau-SC. An bras Dermatol 1993;68(1):17-20.
34. Heenan PJ, English DR, Holman CDJ, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/ 1981 CANCER 1991;68:2079-87.
35. Shaw HM, McCarthy WH. Small-diameter malignant melanoma: A common diagnosis in New South Wales, Australia. J Am Acad Dermatol 1992;27(5-1):679-82.
36. Schmoeckel C, Braun-Falco O. Prognostic index in melanoma. Arch Dermatol 1978;114.871-3.
37. Balch CM, Soong SJ, Murat TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma II prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86(2) 343-51.
38. Ho VC, Sober AJ. Therapy for cutaneous melanoma: An uptodate. J Am Acad Dermatol 1990;22:159-76.
39. Pupin Jr D, Cavegn BM. Biópsias em melanoma maligno. An bras Dermatol 1993;68(3):141-3.
40. Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma? J Am Acad Dermatol 1985;13:983-7.
41. Smoeckel C, Bockelbrink A, Bockelbrink H, Braun-Falco O. Low-and high- risk malignant melanoma-II. multivariate analyses for a prognostic classification. Eur J Cancer et Clin Oncol 1983;19(2):237-43.
42. Taatjes DJ, Arendash-Durand B, von Turkovich M, Trainer TD. HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy. Arch Pathol Lab Med 1993;117:264-8.
43. MacKie RM, Campbell I, Turbitt ML. Use of NK1 C3 monoclonal antibody in the assessment if benign and malignant melanocytic lesions. J Clin Pathol 1984;37:367-72.
44. Nowell PC. The clonal evolution of tumor cell populations. Aquired genetic lability permits stepwise selection of variant sublines and underlines tumor progression. Science 1976;194: 23-8.
45. Suter L, Brocker E-B, Ostmeier H, Schummann J, Clemens S. Metastatic human melanoma, phenotypic heterogeneity and antigen expression in relation to the clinical status. J Cancer Res Clin Oncol 1989;115:459-64.